Eton Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Eton Pharmaceuticals, Inc. (ETON) reported Net Income (Loss) Available to Common Stockholders, Basic of -$27.97 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-16
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -$2.70M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was -$4.96M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-06-30 was -$3.25M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2019-03-31 was -$7.41M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$27.97M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$18.32M.
- Eton Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$37.23M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 5 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | -$27.97M 10-K · filed 2021-03-16 | |||||
| 2019-12-31 | -$2.70M 10-K · filed 2020-03-05 | -$7.66M derived: sum of 2 quarters · filed 2020-03-05 | -$10.91M derived: sum of 3 quarters · filed 2020-03-05 | -$18.32M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$4.96M 10-K · filed 2020-03-05 | -$8.21M derived: sum of 2 quarters · filed 2020-03-05 | -$15.62M 10-Q · filed 2019-11-14 | -$41.69M derived: sum of 4 quarters · filed 2020-03-05 | ||
| 2019-06-30 | -$3.25M 10-K · filed 2020-03-05 | -$10.66M 10-Q · filed 2019-08-06 | -$36.72M derived: sum of 3 quarters · filed 2020-03-05 | -$40.36M derived: sum of 4 quarters · filed 2020-03-05 | ||
| 2019-03-31 | -$7.41M 10-K · filed 2020-03-05 | -$33.47M derived: sum of 2 quarters · filed 2020-03-05 | -$37.11M derived: sum of 3 quarters · filed 2020-03-05 | -$40.91M derived: sum of 4 quarters · filed 2020-03-05 | ||
| 2018-12-31 | -$26.06M 10-K · filed 2020-03-05 | -$29.70M derived: sum of 2 quarters · filed 2020-03-05 | -$33.51M derived: sum of 3 quarters · filed 2020-03-05 | -$37.23M 10-K · filed 2021-03-16 | ||
| 2018-09-30 | -$3.64M 10-K · filed 2020-03-05 | -$7.44M derived: sum of 2 quarters · filed 2020-03-05 | -$11.17M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | -$3.80M 10-K · filed 2020-03-05 | -$7.53M 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | -$3.72M 10-K · filed 2020-03-05 | |||||
| 2017-12-31 | -$8.64M 10-K · filed 2020-03-05 | |||||
| 2017-09-30 | -$3.49M 10-Q · filed 2018-12-20 | -$5.77M 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |